ARKG vs. GNOM ETF Comparison
Comparison of ARK Genomic Revolution Multi-Sector ETF (ARKG) to Global X Genomics & Biotechnology ETF (GNOM)
ARKG
ARK Genomic Revolution Multi-Sector ETF
ARKG Description
Companies within ARKG are focused on and are expected to substantially benefit from extending and enhancing the quality of human and other life by incorporating technological and scientific developments and advancements in genomics into their business. The companies held in ARKG may develop, produce or enable: CRISPR Targeted Therapeutics Bioinformatics Molecular Diagnostics Stem Cells Agricultural Biology ARKG will be concentrated in issuers in any industry or group of industries in the health care sector, including issuers having their principal business activities in the biotechnology industry. ARKG is an actively managed ETF that seeks long-term growth of capital by investing under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including health care, information technology, materials, energy and consumer discretionary, that are relevant to the Fund’s investment theme of the genomics revolution.
Grade (RS Rating)
Last Trade
$23.31
Average Daily Volume
2,216,483
34
GNOM
Global X Genomics & Biotechnology ETF
GNOM Description
The investment seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive Genomics Index ("underlying index"). The fund invests at least 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies that are positioned to benefit from further advances in the field of genomic science and biotechnology, as well as applications thereof (collectively, "Genomics & Biotechnology Companies"), as defined by Solactive AG, the provider of the underlying index. The fund is non-diversified.Grade (RS Rating)
Last Trade
$9.83
Average Daily Volume
42,451
40
Performance
Period | ARKG | GNOM |
---|---|---|
30 Days | -4.11% | -8.82% |
60 Days | -11.01% | -13.25% |
90 Days | -10.33% | -13.40% |
12 Months | -13.96% | -4.66% |
11 Overlapping Holdings
Symbol | Grade | Weight in ARKG | Weight in GNOM | Overlap | |
---|---|---|---|---|---|
BEAM | D | 4.01% | 4.03% | 4.01% | |
CDNA | D | 4.77% | 2.13% | 2.13% | |
CRSP | D | 7.34% | 4.66% | 4.66% | |
ILMN | C | 1.25% | 4.14% | 1.25% | |
MRNA | F | 0.01% | 3.13% | 0.01% | |
NTLA | F | 3.89% | 3.23% | 3.23% | |
NTRA | A | 3.82% | 4.41% | 3.82% | |
PACB | D | 2.16% | 1.18% | 1.18% | |
TXG | F | 3.56% | 2.93% | 2.93% | |
VCYT | B | 4.51% | 4.69% | 4.51% | |
VRTX | D | 1.29% | 2.09% | 1.29% |
ARKG Overweight 23 Positions Relative to GNOM
Symbol | Grade | Weight | |
---|---|---|---|
TWST | F | 8.37% | |
RXRX | D | 7.42% | |
ADPT | C | 5.03% | |
SDGR | C | 4.14% | |
IONS | F | 3.85% | |
NRIX | C | 3.78% | |
GH | B | 3.49% | |
ARCT | F | 3.19% | |
PSNL | D | 2.7% | |
ABSI | F | 2.19% | |
BFLY | A | 1.71% | |
VEEV | C | 1.7% | |
AMGN | D | 1.68% | |
ACCD | F | 1.47% | |
CERS | D | 1.18% | |
INCY | C | 1.11% | |
REGN | F | 0.92% | |
PRME | F | 0.9% | |
CMPS | F | 0.75% | |
MASS | F | 0.69% | |
QSI | B | 0.68% | |
EXAS | D | 0.65% | |
RPTX | F | 0.64% |
ARKG Underweight 29 Positions Relative to GNOM
Symbol | Grade | Weight | |
---|---|---|---|
ARWR | D | -4.31% | |
TECH | F | -4.21% | |
QGEN | D | -4.09% | |
RNA | C | -4.06% | |
A | F | -3.93% | |
BNTX | D | -3.83% | |
BMRN | F | -3.71% | |
ALNY | D | -3.71% | |
RARE | F | -3.63% | |
LEGN | D | -3.56% | |
SRPT | F | -3.55% | |
MYGN | F | -2.8% | |
RCKT | F | -2.62% | |
GILD | B | -2.17% | |
VIR | F | -1.61% | |
MRVI | F | -1.26% | |
SGMO | C | -0.99% | |
RGNX | D | -0.95% | |
ALLO | F | -0.79% | |
VERV | D | -0.74% | |
FLGT | F | -0.73% | |
SANA | F | -0.65% | |
QURE | D | -0.64% | |
EDIT | F | -0.5% | |
PSTX | D | -0.44% | |
CRBU | D | -0.42% | |
TSVT | F | -0.41% | |
LYEL | F | -0.31% | |
SCLX | F | -0.01% |
ARKG: Top Represented Industries & Keywords
GNOM: Top Represented Industries & Keywords